Please login to the form below

Not currently logged in
Email:
Password:

Former Novartis vaccines CMO joins Arterial

Dr Markus Weissbach becomes clinical trials director

Arterial Capital Management, a life science-focused private equity firm, has appointed Dr Markus Weissbach as clinical trials director and a member of its board.

Dr Weissback brings over 25 years of life science industry experience to the post - with particular expertise in cardiology, infectious diseases and oncology - and is currently chief operating officer at DS Biopharma in Dublin.

He recently served as chief medical officer at Novartis Vaccines and Diagnostics, and chief executive officer of Averion International.

Prior to this Weissbach was a director at Takeda Europe, with responsibility for its clinical research and development unit. He also brings expertise from Knoll, CytoTools Biotech, Vasopharm, Cardiorentis, BernaBiotech and Sunesis.

David Evans, director of Arterial, said: “The ability to convert strong science and supporting data into strong investor returns is what makes an outstanding private equity business.

“The addition of Markus to our team is fantastic news for investors and investees alike.”

21st February 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics